Sellas Life Sciences Group Inc (SLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sellas Life Sciences Group Inc (SLS) has a cash flow conversion efficiency ratio of -0.069x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.92 Million) by net assets ($70.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sellas Life Sciences Group Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Sellas Life Sciences Group Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Sellas Life Sciences Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sellas Life Sciences Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sellas Life Sciences Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Truelove Vogue Co Ltd
SHE:003041
|
0.010x |
|
Shenyang Toly Bread Co Ltd
SHG:603866
|
0.043x |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
-0.119x |
|
MetroCity Bankshares
NASDAQ:MCBS
|
0.063x |
|
Nick Scali Ltd
AU:NCK
|
0.239x |
|
Equitas Small Finance Bank Limited
NSE:EQUITASBNK
|
0.013x |
|
Yindu Kitchen Equipment Co Ltd
SHG:603277
|
0.076x |
|
Sichuan Jinshi Technology Co Ltd Class A
SHE:002951
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Sellas Life Sciences Group Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Sellas Life Sciences Group Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Sellas Life Sciences Group Inc (SLS) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.87 Million | $-28.39 Million | -0.401x | +89.29% |
| 2024-12-31 | $9.46 Million | $-35.40 Million | -3.740x | -194.98% |
| 2023-12-31 | $-7.98 Million | $-31.41 Million | 3.938x | +180.24% |
| 2022-12-31 | $4.85 Million | $-23.81 Million | -4.908x | -283.78% |
| 2021-12-31 | $20.35 Million | $-26.02 Million | -1.279x | -243.27% |
| 2020-12-31 | $27.96 Million | $-10.42 Million | -0.373x | +87.13% |
| 2019-12-31 | $6.09 Million | $-17.64 Million | -2.896x | +50.08% |
| 2018-12-31 | $5.25 Million | $-30.42 Million | -5.800x | -9.26% |
| 2017-12-31 | $2.07 Million | $-10.99 Million | -5.309x | -238.71% |
| 2016-12-31 | $28.66 Million | $-44.91 Million | -1.567x | +56.02% |
| 2015-12-31 | $13.51 Million | $-48.16 Million | -3.564x | -208.10% |
| 2014-12-31 | $37.06 Million | $-42.87 Million | -1.157x | +76.45% |
| 2013-12-31 | $5.89 Million | $-28.91 Million | -4.911x | -550.28% |
| 2012-12-31 | $27.76 Million | $-20.96 Million | -0.755x | +47.93% |
| 2011-12-31 | $10.11 Million | $-14.67 Million | -1.451x | +65.63% |
| 2010-12-31 | $2.43 Million | $-10.26 Million | -4.221x | +73.42% |
| 2009-12-31 | $741.00K | $-11.77 Million | -15.883x | -1410.61% |
| 2008-12-31 | $8.97 Million | $-9.43 Million | -1.051x | -88.18% |
| 2007-12-31 | $10.82 Million | $-6.05 Million | -0.559x | -- |
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more